Back to Stocks

ARCT

Arcturus Therapeutics Holdings Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Arcturus Therapeutics is undergoing a strategic transformation, pivoting from a high-burn development phase toward a leaner, milestone-driven commercial model.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The financial reality for Arcturus is stark, characterized by a staggering 93% plunge in total revenue, falling from $29.4 million to just $2.1 million year-over-year.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ARCT filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a crossroads, balancing successful cost-cutting measures against a collapsing primary revenue stream. The dramatic reduction in operating expenses and the maintenance of a $211 million cash cushion provide a necessary safety net, but the sheer scale of the revenue decline and the CSL write-down create a cloud of uncertainty over the long-term valuation. The shift in focus toward rare disease therapeutics like ARCT-810 and ARCT-032 is a strategic necessity as the COVID-19 vaccine market matures and contracts. Ultimately, the investment case now hinges on two factors: the outcome of the CSL arbitration and the ability to convert Phase 2 clinical data into pivotal trial approvals. While the operational lean-out is a positive signal of management's agility, the fundamental risk remains the binary nature of biotech development paired with a partner that has already signaled a loss of confidence in the COVID-19 franchise. Investors are essentially betting on the rare disease pipeline to replace the fading momentum of the vaccine collaboration.

Selected Quarter

Core Takeaway

Arcturus is successfully reducing its operational burn rate to extend its runway, but its primary commercial partnership with CSL is showing significant signs of distress.

Investor Lens

The trade-off is between a disciplined, well-funded balance sheet and a rapidly deteriorating commercial revenue stream.

Watch Next

The outcome of the International Chamber of Commerce arbitration regarding EU milestone payments in Q3 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.10Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Total revenue plummeted 93% year-over-year to $2.1 million.

earnings miss
90%
bullishMay 7

Operating expenses reduced by 33% through strategic headcount and R&D cuts.

margin expansion
60%
bullishMay 7

FDA provided a clear path forward for pivotal pediatric studies for ARCT-810.

regulatory action
70%
neutralMay 7

Company is operating under interim finance leadership following executive transitions.

management change
30%
bearishMay 7

Total revenue plummeted 93% year-over-year to $2.1 million.

earnings miss
90%
bullishMay 7

Operating expenses reduced by 33% through strategic headcount and R&D cuts.

margin expansion
60%
bullishMay 7

FDA provided a clear path forward for pivotal pediatric studies for ARCT-810.

regulatory action
70%
neutralMay 7

Company is operating under interim finance leadership following executive transitions.

management change
30%
bearishMay 7

Total revenue plummeted 93% year-over-year to $2.1 million.

earnings miss
90%
bullishMay 7

Operating expenses reduced by 33% through strategic headcount and R&D cuts.

margin expansion
60%
bullishMay 7

FDA provided a clear path forward for pivotal pediatric studies for ARCT-810.

regulatory action
70%
neutralMay 7

Company is operating under interim finance leadership following executive transitions.

management change
30%
bearishMay 7

Total revenue plummeted 93% year-over-year to $2.1 million.

earnings miss
90%
bullishMay 7

Operating expenses reduced by 33% through strategic headcount and R&D cuts.

margin expansion
60%
bullishMay 7

FDA provided a clear path forward for pivotal pediatric studies for ARCT-810.

regulatory action
70%
neutralMay 7

Company is operating under interim finance leadership following executive transitions.

management change
30%
bearishMay 7

Total revenue plummeted 93% year-over-year to $2.1 million.

earnings miss
90%
bullishMay 7

Operating expenses reduced by 33% through strategic headcount and R&D cuts.

margin expansion
60%
bullishMay 7

FDA provided a clear path forward for pivotal pediatric studies for ARCT-810.

regulatory action
70%
neutralMay 7

Company is operating under interim finance leadership following executive transitions.

management change
30%
bearishMay 7

Total revenue plummeted 93% year-over-year to $2.1 million.

earnings miss
90%
bullishMay 7

Operating expenses reduced by 33% through strategic headcount and R&D cuts.

margin expansion
60%
bullishMay 7

FDA provided a clear path forward for pivotal pediatric studies for ARCT-810.

regulatory action
70%
neutralMay 7

Company is operating under interim finance leadership following executive transitions.

management change
30%
bearishMay 7

Total revenue plummeted 93% year-over-year to $2.1 million.

earnings miss
90%
bullishMay 7

Operating expenses reduced by 33% through strategic headcount and R&D cuts.

margin expansion
60%
bullishMay 7

FDA provided a clear path forward for pivotal pediatric studies for ARCT-810.

regulatory action
70%
neutralMay 7

Company is operating under interim finance leadership following executive transitions.

management change
30%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a crossroads, balancing successful cost-cutting measures against a collapsing primary revenue stream. The dramatic reduction in operating expenses and the maintenance of a $211 million cash cushion provide a necessary safety net, but the sheer scale of the revenue decline and the CSL write-down create a cloud of uncertainty over the long-term valuation. The shift in focus toward rare disease therapeutics like ARCT-810 and ARCT-032 is a strategic necessity as the COVID-19 vaccine market matures and contracts. Ultimately, the investment case now hinges on two factors: the outcome of the CSL arbitration and the ability to convert Phase 2 clinical data into pivotal trial approvals. While the operational lean-out is a positive signal of management's agility, the fundamental risk remains the binary nature of biotech development paired with a partner that has already signaled a loss of confidence in the COVID-19 franchise. Investors are essentially betting on the rare disease pipeline to replace the fading momentum of the vaccine collaboration.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.